The Food and Drug Administration (FDA) will no longer require premarket review of laboratory developed tests (LDTs), including COVID-19 tests, decline to review emergency use authorization (EUA) request for LDTs. Instead, the FDA will prioritize review of EUAs for point-of-care tests, home collection tests, at-home tests, tests that reduce reliance on test supplies, and high-throughput, widely distributed tests.
FDA Will No Longer Review EUA Requests for COVID-19 Laboratory Developed Tests
More Issues
Wade’s Health Law Highlights for October 6, 2026
A federal jury in Fort Worth convicted a Texas licensed professional counselor for a $26 million TRICARE fraud, kickback, and money laundering scheme. Kevin…
Wade’s Health Law Highlights for September 29, 2026
The Department of Justice revised the Justice Manual to limit the use of sub-regulatory guidance in False Claims Act enforcement and to direct attorneys…
Wade’s Health Law Highlights for September 22, 2026
Nearly $12 billion in Medicaid supplemental funding to Texas hospitals will be restored, ending a year-long impasse between Texas and the federal government. Gov.…